Last updated: November 7, 2023
Sponsor: EndoCore Lab s.r.l.
Overall Status: Active - Recruiting
Phase
N/A
Condition
Peripheral Arterial Occlusive Disease
Claudication
Occlusions
Treatment
N/AClinical Study ID
NCT05755412
IVL012022
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age ≥18 years
- Patient has signed an approved informed consent form
- Patient with Critical Limb Ischaemia, Rutherford category 4 (ischaemic rest pain), 5(minor tissue loss) or 6 (major tissue loss)
- Patient with Stenotic (>50% luminal loss) or occluded infrapopliteal artery, includingthe tibiofibular trunk, the anterior tibial artery, the posterior tibial artery andthe peroneal artery
- The vascular lesion length will be no longer than 150 mm.
- Patient with no significant disease at the inflow: common iliac, external iliac,superficial femoral and popliteal artery on the ipsilateral side prior to enrollment,and patient with no significant disease at the outflow - runoff to ankle level:plantar for posterior tibial, pedal for anterior tibial, anterior and posteriorperforant branches for peroneal vessels or previous successful revascularization ofthe disease segments (inflow-outflow)
- Live expectancy > 1 year.
- Presence at least ≥1 filling pedal vessel on the target limb.
Exclusion
Exclusion Criteria:
- Subject pregnant or planning to become pregnant during the study
- Subject no able to perform the follow up or other factors making clinical follow-updifficult
- Acute or Subacute limb ischaemia which requires thrombolysis as first treatmentmodality or previous thrombolytic therapy in the last 48-72 hours.
- Known allergy to concomitant medication, antiplatelet anti-coagulant or thrombolyticmedication
- Poor inflow due to ipsilateral stenoses or occlusions of the iliac or femoropoplitealarteries
- Significant stenoses (> 50%) distal to the target lesion that might requirerevascularization or impede run-off
- Desert foot condition. No Patent foot main arteries
- Subject enrolled in another investigational study that has not reached its primaryendpoint
Study Design
Total Participants: 32
Study Start date:
March 14, 2023
Estimated Completion Date:
March 31, 2025
Study Description
Connect with a study center
I.R.C.C.S. MultiMedica
Sesto San Giovanni, Milano 20099
ItalySuspended
Casa di Cura Abano Terme
Abano Terme, Padova 35031
ItalyActive - Recruiting
Ospedale Pederzoli
Peschiera Del Garda, Veneto 37019
ItalyActive - Recruiting
Arcispedale Santa Maria Nuova
Reggio Emilia, 42123
ItalySuspended
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.